Trial Information
A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan
Inclusion Criteria:
- Adult patients, >=70 years of age
- Non-small cell lung cancer
- Naive to prior chemotherapy or specific immunotherapy
- Presence of at least 1 measurable lesion
Exclusion Criteria:
- Active non-controlled infection or disease
- CNS metastases
- Any other malignancies (other than adequately treated basal cell cancer of skin, or
in situ cancer of the cervix)
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Response rate (partial and complete response)
Outcome Time Frame:
From baseline up to 6 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Chair
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Taiwan: Department of Health
Study ID:
ML20322
NCT ID:
NCT01196078
Start Date:
February 2007
Completion Date:
December 2010
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms